个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
主任医师，医学博士，教授，博士生导师,肝病中心三科主任，脂肪性肝病诊疗中心主任，减重中心主任。首都医科大学传染病学系办公室主任。北京医学会肝病学分会委员；脂肪肝酒精性肝病学组副组长及青年委员会副主任委员；中国研究型医院学会肝病专业委员会脂肪肝与酒精肝学组委员。北京市“十百千”人才项目“百层次人才”，北京市“北京市卫生系统高层次卫生技术人才”项目“学科骨干”。承担国家级、北京市级局级等各类课题23项，其中第一责任人承担7项，发表论文60余篇，SCI4论文6篇。参编著作6部，副主译1部。
擅长领域：酒精性肝病和非酒精性脂肪性肝病的诊断与治疗；各种急慢性肝病的诊断与治疗，尤其是乙型肝炎、丙型肝炎、药物性肝病、重症肝病肝衰竭的救治。
北京佑安医院肝病中心三科同时为脂肪性肝病诊疗中心和减重中心，本中心为中华医学会肝病学分会脂肪肝和酒精性肝病学组认定的“全国脂肪肝规范诊疗中心”，以及中国研究型医院学会肝病专业委员会认定的“中国脂肪性肝病临床研究协作组”成员单位，中国医师协会天士力脂肪肝学院中国医师协会天士力脂肪肝学院《脂肪肝诊治规范学习班》北京培训基地。
十三五《乙肝携带及重症患者临床干预与治疗研究》、十三五《乙型肝炎与肝癌新型血清标记物在北京示范区的推广应用研究》、首发《HCV感染患者应用DAA治疗的真实世界登记研究》、首发《北京市丙型病毒性肝炎发现-转诊-治疗一体化综合管理模式研究》、首发《代谢相关脂肪性肝病关键基因多态性联合检测PCR试剂盒研发及临床验证》、张晶十百千卫生人才专项、张晶市科委HBV糖基化变异在慢加急性肝衰竭预警中的作用
1. Wei H, Zhang J,Li H, Ren H, Hao X, Huang Y. GP73, a new marker for diagnosing HBV-ACLF inpopulation with chronic HBV infections. DiagnMicrobiol Infect Dis..2014,May;79(1):19-24.共同第一 IF 2.568
2. Haiqing Guo,Feng Ren,Li Zhang, Xiangying Zhang,Rongrong Yang,Bangxiang Xie,Zhuo Li,ZhongjieHu,Zhongping Duan,Jing Zhang. Kaempferol induces apoptosis in HepG2 cells viaactivation of the endoplasmic reticulum stress pathway. Mol Med Rep 2016,13（3）: 2791-2800单独通讯作者 IF1.692
3. Zhang J, Gao S, Duan Z, Hu KQ. Overviewon acute-on-chronic liver failure.Front Med. 2016, 10(1): 1–17SCI 收录 IF 1.634
4. Chen Z, Zhang J, Cao L, Zhang N, Zhu J, Ping G, Zhao J, Li S, He Q. Seroprevalence of pertussisamong adults in China where whole cell vaccines havebeen used for 50 years. J Infect. 2016，73, 38-44.共同第一 4.201分
5. Wei X, Wei H, Lin W, Hu Z, Zhang J. Cell death biomarker M65 isa useful indicator of liver inflammation and fibrosis in chronic hepatitis B.Medicine.2017, 96(20): e6807.IF 1.803 单独通讯作者
6. Guo H, Lin W, Zhang X, Zhang X, Hu Z, Li L, Duan Z, Zhang J, Ren F.Kaempferol induces hepatocellular carcinoma cell death via endoplasmicreticulum stress-CHOP-autophagy signaling pathway. Oncotarget,2017 Jul 12. doi:10.18632/oncotarget.19200 5.168共同通讯 IF 5.1
7. Wei Lin#, Jing Zhang#, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li,Shuqin Zhang, Yuexin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, ChenggangJin, Samuel S. Lee*, Zhongping Duan* . A Dynamic Model for Predicting Outcomein Patients with HBV Related Acute-On Chronic Liver Failure. Annals ofHepatology, 2018 17(3):392-402. 共同通讯 IF 1.895
8. Wei X, Yu H,Zhao P, Xie L, Li L, Zhang J. Serum regucalcin is a useful indicator of liverinjury severity in patients with hepatitis B virus-related liverdiseases. Braz J Med Biol Res. 2019;52(10):e8845. 通讯 IF 1.85
9. Tang S, ZhangJ, Mei TT, et al. Association of TM6SF2 rs58542926 T/C gene polymorphism withhepatocellular carcinoma: a meta-analysis. BMC Cancer. 2019;19(1):1128.共第一。IF 2.933
10. Zhang X, Guo L,Zhang X, et al. GLT25D2 Is Critical for Inflammatory Immune Response to PromoteAcetaminophen-Induced Hepatotoxicity by Autophagy Pathway. FrontPharmacol. 2020;11:01187. IF 共同通讯作者 4.225 2区
11. Qiu, L. X.,Liu, Y. L., Lin, W., Liu, Y. R., Yu, H. B., Wang, X. X., Sun, Y. M., Jin, R.H., Hu, Z. J., & Zhang, J. Liver stiffness measurement is a potentpredictor of histological fibrosis regression after hepatitis C virus clearance. EurJ Gastroenterol Hepatol. 2021, 33(4 ): 547-554. IF2.251通讯作者 4区
12. Jing Zhang,Ning Chen, Zhiyun Chen, Yali Liu, Kai Zheng, Yundong Qiu, Nan Zhang, JunpingZhu, Haibin Yu, Qiushui He. Low mannose binding lectin, but not L-ficolin, isassociated with spontaneous clearance of hepatitis C virus after infection. Frontiersin immunology. 2020;11:587669.. IF 5.085 2区 第一 共同第一
13. Tang S, Zhang J, Mei TT, et al. Association of PNPLA3rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease inchildren: a meta-analysis. BMC Med Genet. 2020;21(1):163. Published2020 Aug 18. doi:10.1186/s12881-020-01098-8 1.585 4区
14. Zhang, N., Gou, Y.,Liang, S., Chen, N., Liu, Y., He, Q., & Zhang, J. Dysbiosis of GutMicrobiota Promotes Hepatocellular Carcinoma Progression by Regulating theImmune Response. Journal of immunology research, 2021,4973589. 共同通讯https://doi.org/10.1155/2021/4973589 4.754（2020IF）
15. Liu X, Zhang J, Wei X, Duan Z, Liu H, Chen Y, Liu Y, Lee SS.HBV-related acute-on-chronic liver failure with underlying chronic hepatitishas superior survival compared to cirrhosis. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e734-e739. PMID: 34191757. 共同通讯 2.473
16. Ma L, Liu X, Wu Q, Hu X, Liu H, Zhang J, Lee SS. Role ofAnti-Beta-1-Adrenergic Receptor Antibodies in Cardiac Dysfunction in Patientswith Cirrhotic Cardiomyopathy. J Cardiovasc Transl Res.2022;15(2):381-390. 共同通讯 IF 2020年 4.132
17. Wenyan Zhang1#,Jing Zhang1#, Shan Tang1, Yali Liu1, Xiaofei Du1, Lixia Qiu1, Menglu Liu1,Haibin Yu1*and Calvin Q. Pan2*. Efficacy and Safety of Sofosbuvir-basedRegimens in Hepatitis C Patients With Decompensated Cirrhosis: A SystematicReview and Meta-analysis. Journal of Clinical and Translational Hepatology 共同通讯
18.
参加
19. Liu H, Yoon KT, Zhang J, Lee SS. Advances in cirrhoticcardiomyopathy. Curr Opin Gastroenterol. 2021 May 1;37(3):187-193. doi:10.1097/MOG.0000000000000733. PMID: 33756518 参加
18. Ren W, Zhang J, Chen Y, Wen M, Su Y, Zhao Y,Lu S, Wu J. Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkersin Cirrhotic Patients With or Without Portal Venous Thrombosis. Clin Appl ThrombHemost. 2020 Jan-Dec;26:1076029620982666. doi: 10.1177/1076029620982666. PMID:33356499; PMCID: PMC7768576. 第二作者，参加
<<代谢相关脂肪性肝病临床诊疗手册>> 主编 人民卫生出版社 2022主编
文件上传中...
